Cargando…
Adverse Endocrine-Related Effects of Pembrolizumab Precipitating Severe Hyponatremia
Pembrolizumab is an immune-checkpoint inhibitor (ICI), designed as a highly selective anti-programmed death-1 (PD-1) humanized monoclonal antibody, which ultimately inhibits the negative immune regulation due to PD-1 receptor signaling. This inhibition allows for anti-tumor response and reverses T c...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508894/ https://www.ncbi.nlm.nih.gov/pubmed/36171843 http://dx.doi.org/10.7759/cureus.28393 |